138 related articles for article (PubMed ID: 19800569)
1. Can treating the SYK cell cure leukemia?
Downing JR
Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569
[TBL] [Abstract][Full Text] [Related]
2. Proteomic and genetic approaches identify Syk as an AML target.
Hahn CK; Berchuck JE; Ross KN; Kakoza RM; Clauser K; Schinzel AC; Ross L; Galinsky I; Davis TN; Silver SJ; Root DE; Stone RM; DeAngelo DJ; Carroll M; Hahn WC; Carr SA; Golub TR; Kung AL; Stegmaier K
Cancer Cell; 2009 Oct; 16(4):281-94. PubMed ID: 19800574
[TBL] [Abstract][Full Text] [Related]
3. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
4. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
[TBL] [Abstract][Full Text] [Related]
5. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
6. SYK regulates mTOR signaling in AML.
Carnevale J; Ross L; Puissant A; Banerji V; Stone RM; DeAngelo DJ; Ross KN; Stegmaier K
Leukemia; 2013 Nov; 27(11):2118-28. PubMed ID: 23535559
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
8. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
10. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
11. Activation of spleen tyrosine kinase (Syk) at fertilization in Rhinella arenarum eggs.
Mouguelar VS; Coux G
Int J Dev Biol; 2014; 58(10-12):811-8. PubMed ID: 26154322
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM
Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic prospect of Syk inhibitors.
Ruzza P; Biondi B; Calderan A
Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
[TBL] [Abstract][Full Text] [Related]
14. Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.
Weber C; Schreiber TB; Daub H
J Proteomics; 2012 Feb; 75(4):1343-56. PubMed ID: 22115753
[TBL] [Abstract][Full Text] [Related]
15. β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis.
Oellerich T; Oellerich MF; Engelke M; Münch S; Mohr S; Nimz M; Hsiao HH; Corso J; Zhang J; Bohnenberger H; Berg T; Rieger MA; Wienands J; Bug G; Brandts C; Urlaub H; Serve H
Blood; 2013 May; 121(19):3889-99, S1-66. PubMed ID: 23509157
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
17. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
18. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
[TBL] [Abstract][Full Text] [Related]
19. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Kapoor S
J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
[No Abstract] [Full Text] [Related]
20. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
